← Back

Fecal calprotectin cutoffs: indeterminate colitis vs CD

What is the evidence for fecal calprotectin thresholds to distinguish indeterminate colitis from CD, and how reliable are these cutoffs across laboratories

ContestedNot yet clinician-reviewed

What is known

  • Calprotectin correlates with endoscopic and histologic mucosal inflammation and is used to distinguish inflammatory from non-inflammatory GI conditions, not to subtype IBD. 1–3
  • Reported calprotectin sensitivity and specificity vary across studies depending on the chosen cutoff value. 2,4
  • Fecal markers differentiated IBD from other forms of colitis with only 43–50% overall accuracy. 5
  • In one small pediatric series, indeterminate colitis cases had low calprotectin values, but the numbers were too few to define a distinguishing threshold. 3

What is unknown / caveats

  • Excerpts address calprotectin for diagnosing IBD or detecting inflammation, not for separating IBD subtypes
  • Cutoff performance varies by threshold and assay, and one study could not compute an optimal cutoff because values above 500 were not diluted
  • Indeterminate-colitis data are limited to a few pediatric cases
  • No retrieved study evaluated a calprotectin cutoff specifically to separate indeterminate colitis from [Crohn's disease](https://crohnsology.org (patient sites: crohnz.org)/), so reliability for that use cannot be assessed.

References

  1. Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol. 2016;22(36):8211-8. PMID: 27688663.
  1. Ho SSC, Ross M, Keenan JI, Day AS. Fecal Calprotectin in Combination With Standard Blood Tests in the Diagnosis of Inflammatory Bowel Disease in Children. Front Pediatr. 2020;8:609279. PMID: 33748035.
  1. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33(1):14-22. PMID: 11479402.
  1. Pivac I, Jelicic Kadic A, Despot R, Zitko V, Tudor D, Runjic E, Markic J. Characteristics of the Inflammatory Bowel Disease in Children: A Croatian Single-Centre Retrospective Study. Children (Basel). 2023;10(10). PMID: 37892340.
  1. Turkay C, Kasapoglu B. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. Clinics (Sao Paulo). 2010;65(2):221-31. PMID: 20186307.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.


Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.

Reviewer notes

answered 2026-08-04 · corpus build 71e61f41 · faithfulness 0.875